The schizophrenia market is highly crowded given the presence of numerous antipsychotic therapies including the continued genericization of key oral therapies, the availability of newer oral…
The biosimilar/noninnovator sector of the endocrinology market is evolving. Eli Lilly/Boehringer Ingelheim’s Abasaglar/Basaglar was the first biosimilar/noninnovator insulin glargine to launch in…
MARKET OUTLOOK QUESTIONS ANSWERED What are the treatment drivers and goals for [[indication]]? What drug attributes are key influencers, which have limited impact, and which are hidden…
Market Outlook With four anti-CGRP-targeted MAbs (e.g., Amgen/Novartis’s Aimovig, Teva’s fremanezumab, Eli Lilly’s galcanezumab, and Alder’s eptinezumab) and a novel small molecule (…
The mature rheumatoid arthritis (RA) market boasts ten different biologics representing several distinct drug classes, including blockbuster tumor necrosis factor alpha (TNF-α) inhibitors Enbrel (…
Immune biologics including TNF-alpha inhibitors are among the most commercially successful biopharmaceutical products and therefore offer a great opportunity for biosimilars developers. The…
MARKET OUTLOOK Biguanides and sulfonylureas are by far the most heavily prescribed type 2 diabetes (T2D) drug classes. However, several branded agents are jostling for position as second- and…
Muscular dystrophies (MDs) are a spectrum of genetic disorders characterized by muscle weakness that, in severe disease forms, can lead to loss of ambulation and early death. Duchenne muscular…
MARKET OUTLOOK The human immunodeficiency virus (HIV) therapy market is dynamic and growing as many effective antiretroviral therapies (ARTs), such as Gilead’s Biktarvy, continue to launch,…
MARKET OUTLOOK The human immunodeficiency virus (HIV) therapy market is dynamic and growing as many effective antiretroviral therapies (ARTs), such as Gilead’s Biktarvy, continue to launch,…
The genetic complexity and heterogeneity of gastric and GEJ adenocarcinoma poses a significant challenge for the development of treatment strategies for these cancers. Despite advancements in the…
Market Outlook As one of the larger segments in the overall market for acute pain therapies, the treatment of postoperative pain has experienced substantial growth over the past decade due to the…
MARKET OUTLOOK Sickle cell disease (SCD) is a rare genetic blood disorder characterized by a polymerization of hemoglobin in red blood cells (RBCs) that causes the cells to become distorted into a…
MARKET OUTLOOK Chemotherapy has remained the standard of care for the treatment of ovarian cancer, but new classes of drugs such as angiogenesis inhibitors and, more recently, PARP inhibitors,…
Market Outlook Despite the number of therapy options available, metastatic HR-positive/HER2-negative breast cancer remains incurable and is a major cause of mortality and morbidity in women…
